Not Tagged
Not Tagged
['breast']
 #asco23 sonia trial of 1st v. 2nd line cdk4/6 inhibitor for metastatic breast cancer. primary endpoint efs post two treatments. results: no difference. no quality of life or survival difference. no subgroup benefits from 1st line. 1st line more costly and toxic.
Breast med oncology, chief hem/onc @NYPBrooklyn, prof clinical med @WeillCornell, ethics/spirituality in medicine; long time NY #Jets sufferer; tweets my own